|
Beyond Sedlis: A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation in cervical cancer—A NRG/GOG ancillary analysis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - UE Life Sciences |
|
|
Patents, Royalties, Other Intellectual Property - Tech Transfer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Clovis Oncology; Tesaro |
Research Funding - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Tesaro |
Research Funding - Genmab; NanOlogy; Tesaro; Xenetic Biosciences |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Tesaro |
Speakers' Bureau - Clovis Oncology; Genentech |
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Immunogen (Inst); Janssen (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Pfizer (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst) |
|
|
Consulting or Advisory Role - Altum Pharmaceuticals; Antiva Biosciences; LI-COR Biosciences |
Research Funding - AstraZeneca (Inst); Merck (Inst) |
Expert Testimony - Johnson & Johnson |
|
|
Consulting or Advisory Role - Tesaro |
Speakers' Bureau - Tesaro |
|
|
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst) |
|
|
Consulting or Advisory Role - Bayer (I); EyePoint Pharmaceuticals (I); Eyevensys (I); Novartis (I) |
Research Funding - GOG Partners (Inst) |
|
|
Stock and Other Ownership Interests - Celsion (I) |
|
|
No Relationships to Disclose |
|
|
|